A photo of Michael Jordan.

Member, Division of Bone Marrow Transplantation and Immune Deficiency

Member, Division of Immunobiology

Professor, UC Department of Pediatrics

513-636-1773

513-803-1969

Board Certified

My Biography & Research

Clinical Interests

Histiocytic disorders: HLH and LCH

Research Interests

Better understanding histiocytic disorders and developing novel therapies for them; regulation of the immune response; immunotherapy of cancer

Academic Affiliation

Professor, UC Department of Pediatrics

Divisions

Cancer and Blood Diseases, Immune Deficiencies and Histiocytosis, Bone Marrow Transplantation BMT, Leukemia, Hemophagocytic lymphohistiocytosisHLH, Langerhans Cell Histiocytosis, Autoimmune Liver Disease, Bone Marrow Transplantation, Cancer and Blood Diseases, Immunobiology

Science Blog

NEJM: Emapalumab Clinical Trial Shows Positive Results Against HLH

Rare Diseases

NEJM: Emapalumab Clinical Trial Shows Positive Results Against HLH

Michael B. Jordan, MD5/7/2020

Breakthrough Therapy Improves Life for Children with LRBA Deficiency

Rare Diseases

Breakthrough Therapy Improves Life for Children with LRBA Deficiency

Michael B. Jordan, MD6/28/2019

My Education

MD: UT Southwestern, Dallas, TX, 1993.

Residency: Children's Hospital of Dallas, Dallas, TX, 1996.

Fellowship: The Children's Hospital, Denver, CO, 2002.

Certification: American Board of Pediatrics, 1996; Sub-board of Pediatric Heme/Onc, 2002.

My Publications

Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Chan, AY; Leiding, JW; Liu, X; Logan, BR; Burroughs, LM; Allenspach, EJ; Skoda-Smith, S; Uzel, G; Notarangelo, LD; Slatter, M; et al. Frontiers in Immunology. 2020; 11.

The Variable Genomic NK Cell Receptor Locus Is a Key Determinant of CD4+ T Cell Responses During Viral Infection. Raynor, J; Lin, A; Hummel, SA; Lampe, K; Jordan, M; Hoebe, K; Hildeman, DA. Frontiers in Immunology. 2020; 11.

CD38brightCD8+ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells. Khandelwal, P; Chaturvedi, V; Owsley, E; Lane, A; Heyenbruch, D; Lutzko, CM; Leemhuis, T; Grimley, MS; Nelson, AS; Davies, SM; et al. Biology of Blood and Marrow Transplantation. 2020; 26:1-6.

Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Jordan, MB; Allen, CE; Greenberg, J; Henry, M; Hermiston, ML; Kumar, A; Hines, M; Eckstein, O; Ladisch, S; Nichols, KE; et al. Pediatric Blood and Cancer. 2019; 66.

TNF-mediated compensatory immunity to mycobacterium avium in the absence of macrophage activation by IFN-γ. Resende, M; Cardoso, MS; Frois-Martins, R; Borges, M; Jordan, MB; Castro, AG; Appelberg, R. Journal of immunology (Baltimore, Md. : 1950). 2019; 203:2451-2458.

Identifying and targeting pathogenic PI3K/AKT/ mTOR signaling in IL-6 blockade-refractory idiopathic multicentric Castleman disease. Fajgenbaum, DC; Langan, R; Japp, AS; Partridge, HL; Pierson, SK; Singh, A; Arenas, DJ; Ruth, JR; Nabel, CS; Stone, K; et al. Journal of Clinical Investigation. 2019; 130:4451-4463.

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. La Rosee, P; Horne, A; Hines, M; Greenwood, TV B; Machowicz, R; Berliner, N; Birndt, S; Gil-Herrera, J; Girschikofsky, M; Jordan, MB; et al. Blood. 2019; 133:2465-2477.

CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade. Garcia-Perez, JE; Baxter, RM; Kong, DS; Tobin, R; McCarter, M; Routes, JM; Verbsky, J; Jordan, MB; Dutmer, CM; Hsieh, EW Y. Frontiers in Immunology. 2019; 10.

Clinical responses and persistent BRAF V600E(+) blood cells in children with LCH treated with MAPK pathway inhibition. Eckstein, OS; Visser, J; Rodriguez-Galindo, C; Allen, CE; Zinn, DJ; Peckham-Gregory, EC; Lin, H; Henry, MM; Morland, B; Levy, CF; et al. Blood. 2019; 133:1691-1694.

Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease. Dorjbal, B; Stinson, JR; Ma, CA; Weinreich, MA; Miraghazadeh, B; Hartberger, JM; Frey-Jakobs, S; Weidinger, S; Moebus, L; Franke, A; et al. Journal of Allergy and Clinical Immunology. 2019; 143:1482-1495.